June 25, 2018 – Scenic appoints Ulrich Grau as Chairman of the Board
Scenic Biotech BV, a pioneer in the discovery of genetic modifiers to enable the development of disease modifying therapeutics for rare genetic disorders and other devastating illnesses, today announced that it has appointed Ulrich Grau as Chairman to its Board of Directors.
Ulrich Grau serves also as chairman of i-novion and on the Boards of Affimed and Thermosome. He has over 35 years of experience in the biotechnology and pharmaceutical industries including general management, business development, corporate strategy and the development of new products and technologies. Dr. Grau was Chief Operating Officer at Micromet from 2011 to 2012. Between 2006 and 2010, he was a founder, President and CEO of Lux Biosciences, Inc., a clinical stage ophthalmic company. Previously, he served as CSO at Enzon, and as President of Research and Development at BASF Pharma/Knoll where he directed a global R&D organization whose development pipeline included adalimumab (Humira®). The majority of his career was at Aventis Pharma, where he last held the position of Senior VP of Global Late Stage Development. The long-acting insulin Lantus® is based on his inventions made during his early years as a scientist with Hoechst AG. Ulrich received his Ph.D. in chemistry and biochemistry from the University of Stuttgart and spent three years as a post-doctoral fellow at Purdue University in the field of protein crystallography.